Promising lymphoma combo trial halted early
NCT ID NCT05498220
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tested a new combination of drugs (polatuzumab vedotin plus standard chemotherapy) for people with diffuse large B-cell lymphoma that returned or didn't improve after initial treatment. The goal was to see if the new combo could shrink tumors better than standard therapy alone. Only 5 people enrolled before the study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.